Effects of Naoxinduotai capsule on markers of prothrombotic state in patients with essential hypertension.
- Author:
Jianmei YANG
1
;
Guoyin WANG
;
Youhua WANG
;
Suyun YUAN
;
Duan ZHOU
Author Information
- Publication Type:Journal Article
- MeSH: Aged; Biomarkers; blood; Blood Pressure; drug effects; Capsules; Female; Humans; Hypertension; blood; drug therapy; physiopathology; Male; P-Selectin; blood; Plasminogen Activator Inhibitor 1; blood; Platelet Membrane Glycoproteins; metabolism; Thrombosis; blood; Treatment Outcome
- From: China Journal of Chinese Materia Medica 2010;35(24):3382-3385
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo investigate the effects of Naoxinduotai capsule on the markers of prothrombotic state as plasminogen activator inhibitor-1 (PAI-1), von Willebrand factor (vWF) and alpha-granular membrane protein (CD62p) in essential hypertension patients of yang hyperactivity and blood stagnation.
METHODThe 62 essential hypertension patients of yang hyperactivity and blood stagnation were divided into Naoxinduotai capsule + perindopril group (treatment group, 30 subjects) and Perindopril group (control group, 32 subjects). Clinical symptoms, blood pressure and the blood plasma PAI-1, vWF, CD62p of the patients were observed. The blood plasma PAI-1, vWF and CD62p were measured by enzyme-linked immunosorbant assay (ELISA).
RESULTAfter 8 weeks treatment, in treatment group the clinical symptoms became better, and there was a significant difference with control group (P < 0.05). Blood pressure was significantly degraded, but there was not a significant difference with control group. The blood plasma PAI-1, vWF, CD62p level was degraded ,and there were significant differences with control group in all the three makers (P < 0.05).
CONCLUSIONNaoxinduotai capsule can treat the essential hypertension patients of Yang hyperactivity and blood stagnation, and it has conspicuous advantages in improving the clinical symptoms and the makers of prothrombotic state.
